{
  "docId": "019de075-8d44-7401-b489-ee436db9a207",
  "docSlug": "66ec60e76d61a423395d466c32dc56fb",
  "documentTitle": "Exscientia | Investor Presentation Deck | 75 slides",
  "authorId": "exscientia",
  "authorName": "Exscientia",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 64,
  "pageCount": 75,
  "prevPage": 63,
  "nextPage": 65,
  "slideType": "solution",
  "function": "present_solution",
  "density": "dense",
  "nDataPoints": 0,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-8d44-7401-b489-ee436db9a207/64",
  "deckHref": "/decks/019de075-8d44-7401-b489-ee436db9a207",
  "deckJsonHref": "/decks/019de075-8d44-7401-b489-ee436db9a207.json",
  "deckAnchorHref": "/decks/019de075-8d44-7401-b489-ee436db9a207#slide-64",
  "components": [
    {
      "bbox": {
        "h": 0.25,
        "w": 0.28,
        "x": 0.67,
        "y": 0.32
      },
      "kind": "list",
      "text": "Target Population: May expand therapeutic options for patients with B-cell lymphomas. Confirmed activity in B-cell lymphomas with PM platform",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0e05b911-bb48-4fcc-bb35-c329b6b17b70",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.28,
        "x": 0.07,
        "y": 0.32
      },
      "kind": "list",
      "text": "Better Design: MALT1 protease inhibitor with significantly reduced UGT1A1 inhibition risk combined with potency and selectivity",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "75dd4169-cd0b-4c36-8edc-2cf3c8b3f3c3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.28,
        "x": 0.37,
        "y": 0.32
      },
      "kind": "list",
      "text": "Mechanistic Rationale: MALT1 is required for oncogenic signalling in B-cell and T-cell lymphomas",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9d1c9e3f-8b98-4b56-800c-435d5ad4f9f0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.6,
        "x": 0.2,
        "y": 0.75
      },
      "kind": "paragraph",
      "text": "IND-enabling studies and CMC readiness work ongoing. Additional updates expected in 2H 2023",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ee688378-2500-4882-8f90-8a4a82282c03",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.7,
        "x": 0.07,
        "y": 0.13
      },
      "kind": "title",
      "text": "Allosteric MALT1 protease inhibitor shows significant anti-proliferative activity",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a8073d4f-a053-49ea-9f90-e4340e6c8345",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.07,
        "y": 0.06
      },
      "kind": "title",
      "text": "‘565: Potential to avoid key class-wide safety concern",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7f7ebbf7-c1c8-4ced-8546-b4de17acedec",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Problem-Agitate-Solve (PAS)",
      "slug": "problem-agitate-solve-pas",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "cc24683e-dffd-47cd-9aea-90e273ce3362",
      "evidence": "Target Population: May expand therapeutic options for patients with B-cell lymphomas. Confirmed activity in B-cell lymphomas with PM platform",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}